{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:52:43Z","timestamp":1787662363560,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic membranous nephropathy (IMN) is a common cause of nephrotic syndrome in adults, with current immunosuppressive therapies often limited by incomplete efficacy, significant toxicity, and high cost. Extracts from Tripterygium wilfordii, particularly its glycosides (TWG), have emerged as a potential alternative with immunomodulatory properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and safety of TWG in the treatment of IMN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases from inception to September 2025. Randomized controlled trials (RCTs) and observational studies comparing TWG with standard therapies were included. Risk ratios (RR) and standardized mean differences (SMD) were pooled using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis incorporated 20 studies (1,789 patients). TWG significantly improved the total response rate (RR = 1.27; 95% confidence interval (CI): 1.12\u20131.44), complete remission rate (RR = 1.81; 95% CI: 1.13\u20132.90), and reduced 24-h urinary protein (SMD = \u22122.09; 95% CI: 3.46 to \u22120.71) and recurrence risk (RR = 0.56; 95% CI: 0.37\u20130.86). However, the evidence was characterized by high heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      &amp;gt; 50% for most efficacy outcomes) and a high risk of bias in 17 of the 20 included studies. No significant difference was observed in serum albumin (SMD = 1.20; 95% CI: 0.25\u20132.64) or the overall incidence of inadequately reported adverse events (RR = 0.93; 95% CI: 0.65\u20131.34).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TWG may represent a beneficial therapeutic strategy for IMN, potentially improving remission rates and reducing proteinuria. However, the conclusiveness of these findings is constrained by the high risk of bias in the primary studies, substantial heterogeneity, and inadequate safety reporting. Future robust, multi-regional RCTs are required to definitively establish its efficacy and safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1652789","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:54Z","timestamp":1761888294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keda","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","first-page":"712","article-title":"Efficacy of tripterygium glycosides tablets combined with low-dose hormones in the treatment of idiopathic membranous nephropathy","volume":"43","author":"Ai","year":"2022","journal-title":"Shaanxi J. Traditional Chin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa0810457","article-title":"M-Type phospholipase A2Receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/imna-d-23-00014","article-title":"Diagnosis and treatment of membranous nephropathy in integrative medicine","volume":"11","author":"Bi","year":"2024","journal-title":"Integr. Med. Nephrol. Androl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0000000000001039","article-title":"Updated diagnostic and therapeutic management for membranous nephropathy","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Curr. Opin. Nephrol. and Hypertens."},{"key":"B6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/asn.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B7","volume-title":"Clinical research on the treatment of idiopathic membranous nephropathy with tripterygium wilfordii polyglycoside tablets [D]","author":"Di","year":"2019"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/nejmoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","first-page":"3284","article-title":"The curative effect of Tripterygium wilfordii polyglycosides combined with low-dose hormones in the treatment of idiopathic membranous nephropathy and its effect on serum ET-I levels in patients","volume":"28","author":"Gao","year":"2017","journal-title":"Hainan Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/0886022x.2021.1918555","article-title":"Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria","volume":"43","author":"Guo","year":"2021","journal-title":"Ren. Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijbiomac.2018.06.040","article-title":"Methylglyoxal modified IgG generates autoimmune response in rheumatoid arthritis","volume":"118","author":"Islam","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15887\/j.cnki.13-1389\/r.2023.01.006","article-title":"Clinical effect of tripterygium glycosides combined with leflunomide and low-dose hormones in the treatment of idiopathic membranous nephropathy","volume":"16","author":"Jiang","year":"2023","journal-title":"Clin. Ration. Drug Use"},{"key":"B13","doi-asserted-by":"publisher","first-page":"949312","DOI":"10.3389\/fphar.2022.949312","article-title":"Inflammation aggravated the hepatotoxicity of triptolide by oxidative stress, lipid metabolism disorder, autophagy, and apoptosis in zebrafish","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B14","first-page":"211","article-title":"The curative effect of tripterygium wilfordii polyglycosides combined with tacrolimus in the treatment of idiopathic membranous nephropathy and its effect on urinary C5b-9 IgG4","volume":"26","author":"Liang","year":"2020","journal-title":"Hebei Med."},{"key":"B15","first-page":"4997","article-title":"Clinical observation of tripterygium glycosides combined with valsartan in the treatment of idiopathic membranous nephropathy","author":"Ling","year":"2015","journal-title":"China Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12882-015-0199-x","article-title":"Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study","volume":"16","author":"Liu","year":"2015","journal-title":"BMC Nephrol."},{"key":"B17","first-page":"1786","article-title":"Clinical research on tripterygium wilfordii polyglycosides combined with small doses of prednisone in the treatment of senile idiopathic membranous nephropathy","volume":"17","author":"Liu","year":"2017","journal-title":"Mod. Hosp."},{"key":"B18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/mnh.0000000000000876","article-title":"The expanding spectrum and utility of antigens in membranous nephropathy","volume":"32","author":"Miller","year":"2023","journal-title":"Curr. Opin. Nephrol. and Hypertens."},{"key":"B19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.13699\/j.cnki.1001-6821.2015.11.003","article-title":"Clinical research on low-dose tacrolimus combined with tripterygium glycosides in the treatment of idiopathic membranous nephropathy","volume":"31","author":"Peng","year":"2015","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B21","first-page":"337","article-title":"A prospective randomized controlled study of tripterygium glycosides tablets in the treatment of idiopathic membranous nephropathy with moderate proteinuria","volume":"22","author":"Qiu","year":"2021","journal-title":"Chin. J. Integr. Traditional West. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.13683\/j.wph.2016.03.012","article-title":"Curative effect observation of tripterygium wilfordii polyglycoside combined with angiotensin II receptor antagonist in the treatment of idiopathic membranous nephropathy","volume":"37","author":"Qu","year":"2016","journal-title":"World Clin. Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/asn.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12882-018-0967-5","article-title":"Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy","volume":"19","author":"Shang","year":"2018","journal-title":"BMC Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"774414","DOI":"10.3389\/fphar.2021.774414","article-title":"New insights into the effects of individual Chinese herbal medicines on chronic kidney disease","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2) R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/nejmoa1409354","article-title":"Thrombospondin Type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1091581819864518","article-title":"Autophagy in Triptolide-Mediated cytotoxicity in hepatic cells","volume":"38","author":"Wei","year":"2019","journal-title":"International Journal of Toxicology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"910923","DOI":"10.3389\/fphar.2022.910923","article-title":"Differences in multicomponent pharmacokinetics, tissue distribution, and excretion of tripterygium glycosides tablets in normal and adriamycin\u2013induced nephrotic syndrome rat models and correlations with efficacy and hepatotoxicity","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e22394","DOI":"10.1002\/jbt.22394","article-title":"Toxic effects of triptolide on adrenal steroidogenesis in H295R cells and female rats","volume":"33","author":"Xu","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B34","first-page":"259","article-title":"The curative effect of tripterygium wilfordii polyglycosides combined with benazepril on elderly patients with primary membranous glomerulonephritis and its influence on inflammatory indicators","volume":"41","author":"Yang","year":"2018","journal-title":"Drug Eval. Res."},{"key":"B35","first-page":"676","article-title":"Clinical efficacy analysis of mycophenolate mofetil combined with tripterygium glycosides in the treatment of idiopathic membranous nephropathy","volume":"29","author":"Yang","year":"2015","journal-title":"South China Natl. Def. Med. J."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/imna-d-23-00004","article-title":"Use of Chinese herbal medicine to inhibit podocyte damage as therapeutic strategy for membranous nephropathy","volume":"10","author":"Zhang","year":"2023","journal-title":"Integr. Med. Nephrol. Androl."},{"key":"B37","first-page":"764","article-title":"Analysis of the effect of tripterygium glycosides combined with tacrolimus in the treatment of nephrotic syndrome","volume":"36","author":"Zhao","year":"2022","journal-title":"Chin. J. Sch. Dr."},{"key":"B38","first-page":"1795","volume-title":"Observation on the efficacy of multi-target tacrolimus and tripterygium glycosides in the treatment of idiopathic membranous nephropathy","author":"Zhou","year":"2020"},{"key":"B39","first-page":"507-511","article-title":"A prospective randomized controlled trial of tripterygium glycosides in the treatment of idiopathic membranous nephropathy","volume":"23","author":"Zuo","year":"2012","journal-title":"J. Nephrol. Dial. Renal Transplant."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1652789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:58Z","timestamp":1761888298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1652789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1652789"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1652789","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1652789"}}